AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9069483
Drug: Active warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active warfarin and placebo aspirin
Trial: 9069483
Drug: Placebo warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo warfarin and active aspirin
Trial: 29929169
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA + posterior QLB with 0.3 ml/kg 0.25% bupivacaine
Trial: 29929169
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA + posterior QLB with 0.3 ml/kg 0.9% saline
Trial: 24929235
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of emtricitabine and TDF (FTC/TDF)
Trial: 29143869
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg
Trial: 3440636
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg
Trial: 17205319
Drug: Haloperidol 3
RxNorm normalized name: Haloperidol 300 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 3 mg
Trial: 2149042
Drug: Teicoplanin at
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin at a dose of 400 mg/d
Trial: 82086
Drug: Cimetidine 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1.6 g daily for 6 weeks
Trial: 1632401
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor
Trial: 16923922
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II type 1 receptor antagonist
Trial: 16923922
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Angiotensin-converting enzyme inhibitor + Angiotensin II type 1 receptor antagonist)
Trial: 15217999
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg daily from day 3-7 and recombinant FSH (rFSH) 75 IU/day on days 3 and 8
Trial: 15217999
Drug: Long GnRH
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long GnRH agonist protocol and stimulated with rFSH (300-450 IU/day)
Trial: 11526368
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AADs) - primarily amiodarone
Trial: 3306748
Drug: Caffeine 240
RxNorm normalized name: aspirin/acetaminophen/caffeine 240 mg-125 mg-32 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 240 mg
Trial: 3306748
Drug: Caffeine 480
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 480 mg
Trial: 3306748
Drug: Caffeine 720
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 720 mg
Trial: 28744796
Drug: ABT-122 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (0.1, 0.3, 1, 3, and 10 mg/kg intravenous; 0.3, 1, and 3 mg/kg subcutaneous)
Trial: 28744796
Drug: ABT-122 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (1 mg/kg every other week or 0.5-3 mg/kg every week for 8 weeks)
Trial: 28744796
Drug: ABT-122 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (1 mg/kg every other week)
Trial: 28744796
Drug: ABT-122 (0.5-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (0.5-3 mg/kg every week)
Trial: 28744796
Drug: ABT-122 (every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (every week dosing)
Trial: 27053384
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (3 times daily 117 mg or 350 mg/d)
Trial: 20861645
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus L-92
Trial: 20079899
Drug: metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (500 mg three times a day) plus simvastatin (20 mg/day)
Trial: 20079899
Drug: metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (500 mg three times a day) plus placebo
Trial: 18462468
Drug: NTrainer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTrainer treatment provided to 21 infants.
Trial: 18462468
Drug: NTrainer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTrainer treatment
Trial: 15998657
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (400 IU/day of vitamin E, 500 mg/day of vitamin C, 6 mg/day of beta-carotene)
Trial: 8734674
Drug: Once-daily aminoglycosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily aminoglycosides
Trial: 6343340
Drug: Oral fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenoterol 0.8 mg/kg in three divided doses
Trial: 6343340
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol (higher than 0.4 mg three times per day)
Trial: 28002165
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) >14 ng/L and NT-proBNP >300 ng/L
Trial: 28002165
Drug: NT-proBNP cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP cutoff at 108 ng/L
Trial: 25770644
Drug: KETODEX (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KETODEX (low-dose ketamine 0.15 mg/kg followed by dexmedetomidine 0.3 μg/kg i.v.)
Trial: 18679038
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment for 6 weeks
Trial: 10826241
Drug: Behavioral Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Family Systems Therapy (BFST)
Trial: 3921278
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diltiazem and propranolol
Trial: 29206720
Drug: HIV prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV prevention intervention providing 80% reduction in susceptibility per act; specific dosage and duration not mentioned.
Trial: 28770449
Drug: 30,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30,000 IU oral VitD3/week
Trial: 26791798
Drug: pemetrexed +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemetrexed + cisplatin (500 mg/m² + 75 mg/m²)
Trial: 26791798
Drug: pemetrexed +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemetrexed + carboplatin (500 mg/m² + AUC5)
Trial: 22024529
Drug: Opened capsule
RxNorm normalized name: naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opened capsule dosing method (30 mg)
Trial: 22024529
Drug: Intact capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact capsule dosing method (30 mg)
Trial: 12420014
Drug: Intra-oral lubricating
RxNorm normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-oral lubricating device
Trial: 13678775
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg i.v. neridronate bimonthly and 500 mg calcium plus 400 U vitamin D supplements daily (n=39)
Trial: 13678775
Drug: Calcium-vitamin D
RxNorm normalized name: Calcium-Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin D supplements alone (control group, n=39)
Trial: 10916115
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg/day (group A)
Trial: 8956382
Drug: Ritanserin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin 2.5 mg/day or 5 mg/day
Trial: 1388038
Drug: Clodronate 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 300 mg/day plus hydration
Trial: 27482970
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg esmirtazapine
Trial: 27482970
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg esmirtazapine
Trial: 27482970
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg esmirtazapine
Trial: 8677929
Drug: Salbutamol inhalation
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol inhalation
Trial: 7599664
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) administration of human menopausal gonadotropin (hMG) 150 IU
Trial: 7599664
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of human menopausal gonadotropin (hMG) 150 IU
Trial: 912132
Drug: Topical nitrogen
RxNorm normalized name: nitrogen Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitrogen mustard with and without tolerance induction
Trial: 912132
Drug: PUVA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA in combination with Cyclophosphamide
Trial: 30986736
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy with integrated elements of emotion‐focused therapy (CBT + EFT)
Trial: 30986736
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy with treatment components based on self‐regulation theory (CBT + SR)
Trial: 25929897
Drug: Probiotic preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation (28 capsules over 14 days, twice a day)
Trial: 25929897
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (matching to probiotic preparation)
Trial: 23587104
Drug: Self-administered structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered structured questionnaire assessing sexual health knowledge
Trial: 17103172
Drug: Etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept treatment group
Trial: 15521667
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amphotericin B and endoscopic surgery, associated or not with Caldwell‐Luc surgery
Trial: 2224121
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) 150 or 300 U/kg via intravenous (IV) bolus
Trial: 2224121
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) 150 or 300 U/kg via subcutaneous (SC) injection
Trial: 78095
Drug: Oestrogen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen treatment for first 4 years, followed by withdrawal
Trial: 78095
Drug: Oestrogen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen treatment (first 4 years) vs. Placebo (full 8 years)
Trial: 25575940
Drug: Fluticasone/formoterol (100/10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol (100/10, 250/10 or 500/20 μg b.i.d.)
Trial: 25575940
Drug: Fluticasone (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (100, 250 or 500 μg b.i.d.)
Trial: 23070786
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural group psychotherapy plus open methylphenidate treatment
Trial: 11475711
Drug: Braun/Oral-B D7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun/Oral-B D7 powered toothbrush
Trial: 11475711
Drug: Oral-B Advantage
RxNorm normalized name: Advantage Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Advantage B35 manual toothbrush
Trial: 27879044
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract (PE) - dose-2 (640 mg phenolics/day)
Trial: 24958282
Drug: DNA-damaging agents
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA-damaging agents
Trial: 15572639
Drug: Interviewer administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer administered mode (Control)
Trial: 9055142
Drug: Eprosartan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (200 mg orally twice daily for 7 days)
Trial: 9055142
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching oral doses for 7 days)
Trial: 31216537
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (tolvaptan and reduced furosemide doses)
Trial: 31216537
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (original furosemide dosage)
Trial: 30216917
Drug: Methylphenidate, fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate, fixed dose
Trial: 26935057
Drug: Low-dose CpG-B
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CpG-B (CpG)
Trial: 26935057
Drug: Low-dose CpG-B
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CpG-B (CpG) + GM-CSF (GM)
Trial: 20150394
Drug: Oral lipoic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lipoic acid (1200 mg) - Formulation A
Trial: 20150394
Drug: Oral lipoic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lipoic acid (1200 mg) - Formulation B
Trial: 20150394
Drug: Oral lipoic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lipoic acid (1200 mg) - Formulation C
Trial: 20150394
Drug: Subcutaneous lipoic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lipoic acid (20 mg/kg)
Trial: 20150394
Drug: Subcutaneous lipoic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lipoic acid (50 mg/kg)
Trial: 20150394
Drug: Subcutaneous lipoic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lipoic acid (100 mg/kg)
Trial: 18333864
Drug: Maraviroc 100
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc 100 mg b.i.d. + rifampicin 600 mg q.d.
Trial: 18333864
Drug: Maraviroc 100
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc 100 mg b.i.d. + efavirenz (EFV) 600 mg q.d.
Trial: 18333864
Drug: Maraviroc 200
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc 200 mg b.i.d. + rifampicin or EFV
Trial: 18333864
Drug: Maraviroc 300
RxNorm normalized name: maraviroc 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc 300 mg b.i.d. + LPV/r (lopinavir 400 mg + ritonavir 100 mg)
Trial: 18333864
Drug: Maraviroc 100
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc 100 mg b.i.d. + SQV/r (saquinavir 1000 mg + ritonavir 100 mg)
Trial: 23864314
Drug: Levodopa administration
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa administration
Trial: 10412882
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg OD
Trial: 540429
Drug: alpha‐receptor blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐receptor blockade (phentolamine 10 mg intravenously)
Trial: 540429
Drug: combined alpha‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined alpha‐ and beta‐ receptor blockade (labetalol 100 mg intravenously)
Trial: 31641967
Drug: PBMT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT + nonsurgical periodontal treatment (NSPT)
Trial: 31641967
Drug: nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nonsurgical periodontal treatment (NSPT)
Trial: 24002370
Drug: Atomoxetine 40
RxNorm normalized name: atomoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 40 mg
Trial: 23692383
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg diclofenac HPβCD
Trial: 23692383
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac HPβCD
Trial: 23692383
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg diclofenac HPβCD
Trial: 19237898
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of piperacillin (6 patients)
Trial: 19237898
Drug: Bolus dosing
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dosing of piperacillin (7 patients)
Trial: 16815689
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of piperacillin
Trial: 19237898
Drug: Bolus dosing
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dosing of piperacillin
Trial: 17154733
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy
Trial: 17541052
Drug: Dynamic supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic supportive treatment
Trial: 26170105
Drug: Fingolimod 0.5
RxNorm normalized name: fingolimod 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 0.5 mg
Trial: 24195864
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg FeSO4
Trial: 16259175
Drug: Low-intensity ultrasound
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity ultrasound therapy (20 minutes daily for six weeks)
Trial: 7674504
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (antianginal therapy)
Trial: 2206076
Drug: Oral terbutaline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline, 2.5 to 5 mg every 3 to 4 hours
Trial: 2206076
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium oxide, 200 mg every 3 to 4 hours
Trial: 6930206
Drug: Labetalol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (400 mg/day first month, average 585 mg/day second month)
Trial: 6930206
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 mg/day first month, average 234 mg/day second month)
Trial: 6930206
Drug: Labetalol (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (higher dose)
Trial: 6930206
Drug: Labetalol with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol with diuretic
Trial: 6930206
Drug: Propranolol (long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (long term therapy)
Trial: 31365109
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment aimed at decreasing systolic BP by 10%-25% within the first 24 hours, achieving systolic BP <140 mm Hg and diastolic BP <90 mm Hg within 7 days, and maintaining this level during hospitalization.
Trial: 31365109
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (discontinued all antihypertensive medications)
Trial: 17143194
Drug: Aliskiren monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren monotherapy (75, 150 or 300 mg)